The fair value of requested stock should be $99.54
* Note: Prices are in Million (M) USD.
Description:
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
These criteria used Company’s Cash, EBITDA and Debt balance to determines its fair value:
Cash : $987 M
Debt : $7,610 M
EBITDA : $0 M
Net Debt (Debt - Cash): $6,623 M
This criteria used industry in which company operates:
Sector: Healthcare
Industry: Biotechnology
Based on industry, 5 points assigned.
This criteria used Company’s Price To Earning (P/E) Ratio to determines its fair value:
Forward PE Ratio: 6.78
Since Forward PE Ratio is less than 15, 5 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Average Free Cash Flow: $298 M
Average Revenue: $1,000 M
Free Cash Flow to Revenue : 30 %
Since Free Cash Flow (FCF) to Revenue percentage is greater than 25, 5 points assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $2,264 M
Revenue 4 Years Ago (2020-12-31): $2,122 M
Last 5 Years Average Revenue Growth: 1%
Since Revenue Growth is between 0 - 5, 1 point assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $593 M
Share Count 5 Years Ago (2020-12-31): $375 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Earnings Per Share (EPS): $4.81
Dividend Per Share (DPS): $1
Payout Ratio: 17%
Dividend Yield: 3%
Since company Payout Ratio is less than 50, 2 points assigned.
Since Dividend Yield is greater than 2, 2 points assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Average ROE: 5%
Since Average ROE is less than 10, 1 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $33
52-Week Low: $24
Threshold Price (15% Above 52-Week Low): $27
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $18,889 M
Since Market Cap is between 10B - 100B, 2 points assigned.
% Exposure to Total Portfolio
Based on the calculated score, we recommend do not exceed 3% exposure of Total Portfolio.
Value-Trade has assigned 23 points to above Royalty Pharma Plc (RPRX) stock.
Twenty Years Avg PE 9, Fair Value PE 25, Industry Based PE is 20 and Growth based PE is 8. Based on these all values average assigned is 15.50.
Value-Trades has assined P/E value 15.50. Since current year earning per share is $4.81.
The fair value of Royalty Pharma Plc (RPRX) stock should be (15.50 x $4.81) = $74.56
